208 related articles for article (PubMed ID: 37967215)
21. Knockdown of HMGB1 inhibits the crosstalk between oral squamous cell carcinoma cells and tumor-associated macrophages.
Wen J; Yin P; Su Y; Gao F; Wu Y; Zhang W; Chi P; Chen J; Zhang X
Int Immunopharmacol; 2023 Jun; 119():110259. PubMed ID: 37141670
[TBL] [Abstract][Full Text] [Related]
22. The role of tumor-associated macrophage in breast cancer biology.
Choi J; Gyamfi J; Jang H; Koo JS
Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373
[TBL] [Abstract][Full Text] [Related]
23. Regulation of tumor-associated macrophage (TAM) differentiation by NDRG2 expression in breast cancer cells.
Lee S; Lee A; Lim J; Lim JS
BMB Rep; 2022 Feb; 55(2):81-86. PubMed ID: 34743782
[TBL] [Abstract][Full Text] [Related]
24. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
Gao J; Liang Y; Wang L
Front Immunol; 2022; 13():888713. PubMed ID: 35844605
[TBL] [Abstract][Full Text] [Related]
25. Blocking siglec-10
Xiao N; Zhu X; Li K; Chen Y; Liu X; Xu B; Lei M; Xu J; Sun HC
Exp Hematol Oncol; 2021 Jun; 10(1):36. PubMed ID: 34112250
[TBL] [Abstract][Full Text] [Related]
26. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
[TBL] [Abstract][Full Text] [Related]
27. Metabolism drives macrophage heterogeneity in the tumor microenvironment.
Li S; Yu J; Huber A; Kryczek I; Wang Z; Jiang L; Li X; Du W; Li G; Wei S; Vatan L; Szeliga W; Chinnaiyan AM; Green MD; Cieslik M; Zou W
Cell Rep; 2022 Apr; 39(1):110609. PubMed ID: 35385733
[TBL] [Abstract][Full Text] [Related]
28. Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.
Glasgow NG; Povysheva NV; Azofeifa AM; Johnson JW
J Neurosci; 2017 Oct; 37(40):9686-9704. PubMed ID: 28877967
[TBL] [Abstract][Full Text] [Related]
29. Siglec-9
Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
[TBL] [Abstract][Full Text] [Related]
30. Tailoring biomaterials and applications targeting tumor-associated macrophages in cancers.
Jing F; Liu X; Chen X; Wu F; Gao Q
Front Immunol; 2022; 13():1049164. PubMed ID: 36439188
[TBL] [Abstract][Full Text] [Related]
31. Turning enemies into allies-reprogramming tumor-associated macrophages for cancer therapy.
Molgora M; Colonna M
Med; 2021 Jun; 2(6):666-681. PubMed ID: 34189494
[TBL] [Abstract][Full Text] [Related]
32. The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma.
Zhang L; Jiang Y; Zhang G; Wei S
Front Immunol; 2023; 14():1238233. PubMed ID: 37731483
[TBL] [Abstract][Full Text] [Related]
33. Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies.
Kitamura T
Essays Biochem; 2023 Sep; 67(6):1003-1014. PubMed ID: 37313600
[TBL] [Abstract][Full Text] [Related]
34. Tumor-associated macrophages in tumor progression and the role of traditional Chinese medicine in regulating TAMs to enhance antitumor effects.
Zhang J; Gao J; Cui J; Wang Y; Jin Y; Zhang D; Lin D; Lin J
Front Immunol; 2022; 13():1026898. PubMed ID: 36311793
[TBL] [Abstract][Full Text] [Related]
35. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
[TBL] [Abstract][Full Text] [Related]
36. Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors.
Anfray C; Varela CF; Ummarino A; Maeda A; Sironi M; Gandoy S; Brea J; Loza MI; León S; Calvo A; Correa J; Fernandez-Megia E; Alonso MJ; Allavena P; Crecente-Campo J; Andón FT
Front Immunol; 2023; 14():1334800. PubMed ID: 38259462
[TBL] [Abstract][Full Text] [Related]
37. Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy.
Liu L; Chen G; Gong S; Huang R; Fan C
Front Immunol; 2023; 14():1274547. PubMed ID: 38022518
[TBL] [Abstract][Full Text] [Related]
38. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8
Ma S; Sun B; Duan S; Han J; Barr T; Zhang J; Bissonnette MB; Kortylewski M; He C; Chen J; Caligiuri MA; Yu J
Nat Immunol; 2023 Feb; 24(2):255-266. PubMed ID: 36658237
[TBL] [Abstract][Full Text] [Related]
39. Targeting tumor-associated macrophages for cancer immunotherapy.
Shu Y; Cheng P
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188434. PubMed ID: 32956767
[TBL] [Abstract][Full Text] [Related]
40. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing.
Zins K; Abraham D
Methods Mol Biol; 2020; 2115():289-325. PubMed ID: 32006408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
